Bruni J V & Co. Co. Purchases New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Bruni J V & Co. Co. initiated a position in IQVIA during the second quarter, purchasing 66,918 shares. Institutional investors collectively own approximately 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted EPS and $4.37 billion in revenue, with revenue increasing 8.7% year over year. The company also authorized a $2 billion share-repurchase program, covering up to 6.8% of its shares.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus rating and an average price target of $241.88; price targets range as high as $276. IQVIA shares recently traded at $240.25, near the consensus target.

Bruni J V & Co. Co. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 66,918 shares of the medical research company's stock, valued at approximately $12,929,896,000. IQVIA accounts for about 1.2% of Bruni J V & Co. Co.'s investment portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company's stock worth $4,429,426,000 after buying an additional 159,899 shares during the period. BlackRock Inc. bought a new stake in IQVIA during the second quarter worth about $2,811,292,000. Geode Capital Management LLC grew its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners increased its stake in shares of IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock valued at $923,276,000 after purchasing an additional 530,672 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 0.4%

IQVIA stock opened at $240.25 on Wednesday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36. The business's fifty day moving average is $208.88 and its 200 day moving average is $186.72. The stock has a market capitalization of $39.54 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA's revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has initiated a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.

Insider Activity at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business's stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last three months. 1.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price objective on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Barclays reissued an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. Mizuho upped their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Finally, Stifel Nicolaus increased their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source